JOIN The UK's Largest
Primary Care Pharmacy Network

Details

Webinar: Part 2: Optimising Anticoagulation For Stroke Prevention in Patients with NVAF - Switching from Warfarin to a NOAC 8-9pm

June 17, 2021

zoom online

Event Summary:

Part 2: Switching from Warfarin to a NOAC

 An interactive discussion on the latest recommendations for practical management of anticoagulation in patients with NVAF ( non-valvular atrial fibrillation)

Speaker: Lynne Garforth

Objectives

  • Case study: following a patient who is switched from warfarin to apixaban
  • Key changes in the latest 2021 NICE guidance
  • The use of ORBIT as a bleeding risk score tool
  • DOACs as first-line treatment for newly diagnosed patients with NVAF
  • To discuss the option of switching to a DOAC in patients with NVAF who are already taking a VKA and are stable.

 

This promotional content has been organised and funded by Bristol Myers Squibb on behalf of the BMS/Pfizer Alliance. This is intended for UK Healthcare Professionals only. Treatment options will be discussed at this meeting. For Eliquis® (apixaban) prescribing information and adverse event reporting, please click here.

 

Sign up for this Event using the form below:

Please note that all fields marked with an asterisk (*) are mandatory.


If you have a NHS.NET address please add pcpa@pcpa.org.uk to your contacts.
If PCPA is not a saved contact, you may not receive your log in details

PCPA provide all exhibitors with a full delegate list. This includes name, job title and organisation and does not contain any contact details. By registering for this event, you are in agreement with this information to be shared in a closed environment.